

【研究業績】

<発表論文>

原著

(研究室主体)

1. Takeuchi S, Yanagitani N, Seto T, Hattori Y, Ohashi K, Morise M, Matsumoto S, Yoh K, Goto K, Nishio M, Takahara S, Kawakami T, Imai Y, Yoshimura K, Tanimoto A, Nishiyama A, Murayama T, Yano S. Phase I/II study of alectinib in RET-rearranged previously-treated non-small cell lung cancer (ALK-RET). **Transl Lung Cancer Res** 2021, 10(1):314-25, doi: 10.21037/tlcr-20-549.
2. Nishiyama A, Sakaguchi H, Yanagimura N, Suzuki C, Otani S, Tanimoto A, Yamashita K, Takeuchi S, Otubo K, Yano S. Bronchoesophageal fistula formation after three courses of nivolumab for carcinoma of unknown primary with a subgroup of lung squamous cell carcinoma. **Oxford Medical Case Reports** 2020 Dec 28;2020(12):omaai116.
3. Nishiyama A, Staub Y, Suga Y, Fujita M, Tanimoto A, Ohtsubo K, Yano S. Sarcopenia may influence the prognosis in advanced thyroid cancer patients treated with molecular targeted therapy. **In Vivo** 2021;35(1):401-10.
4. Tanimoto A, Matsumoto S, Takeuchi S, Arai S, Fukuda K, Nishiyama A, Goto K, Yano S. Proteasome inhibition overcomes ALK-TKI resistance by p53 inactivation through Noxa expression in ALK-rearranged NSCLC. **Clin Cancer Res**, 2020 Dec 11. doi: 10.1158/1078-0432.CCR-20-2853. Online ahead of print.
5. Ohtsubo K, Yamashita K, Yanagimura N, Suzuki C, Tanimoto A, Nishiyama A, Takeuchi S, Iwaki N, Kawano M, Izumozaki A, Inoue D, Gabata T, Ikeda H, Watanabe M, Yano S. Multiple malignant lymphomas of the bile duct developing after spontaneous regression of an autoimmune pancreatitis-like mass. **Int Med**, 2021 Feb 1;60(3):409-415. doi: 10.2169/internalmedicine.5429-20.
6. Wang R, Yamada T, Kita K, Taniguchi H, Arai S, Fukuda K, Terashima M, Ishimura A, Nishiyama A, Tanimoto A, Takeuchi S, Ohtsubo K, Yamashita K, Yamano T, Yoshimura A, Takayama K, Kaira K, Taniguchi Y, Atagi S, Uehara H, Hanayama R, Matsumoto I, Han X, Matsumoto K, Wang W, Suzuki T, Yano S. Transient IGF-1R inhibition combined with osimertinib eradicates AXL-low expressing EGFR mutated lung cancer. **Nat Commun** 2020 Sep 14;11(1):4607.
7. Arai S, Takeuchi S, Fukuda K, Tanimoto A, Nishiyama A, Konishi H, Takagi A, Takahashi H, Ong ST, Yano S. Resminostat, a histone deacetylase inhibitor, circumvents tolerance to EGFR inhibitors in EGFR-mutated lung cancer cells with BIM deletion polymorphism. **J Med Invest** 2020;67(3.4):343-50.
8. Nishiyama A, Takeuchi S, Adachi Y, Otani S, Tanimoto A, Sasaki M, Matsumoto S, Goto K, Yano S. MET amplification results in heterogeneous responses to osimertinib in EGFR-mutant lung cancer previously treated with erlotinib, **Cancer Sci** 2020;111(10):3813-23.
9. Fukuda K, Takeuchi S, Arai S, Kita K, Tanimoto A, Nishiyama A, Yano S. Glycogen synthase kinase-3 inhibition overcomes epithelial-mesenchymal transition-associated resistance to osimertinib in EGFR-mutant lung cancer. **Cancer Sci** 2020;111:2374-84.

10. Adachi Y, Yanagimura N, Suzuki C, Otani S, Tanimoto A, Nishiyama A, Yamashita K, Ohtsubo K, Takeuchi S, Yano S. Reduced doses of dabrafenib and trametinib combination therapy for BRAF V600E-mutant non-small cell lung cancer prevent rhabdomyolysis and maintain tumor shrinkage: a case report. **BMC Cancer** 2020 Feb 24;20(1):156.
11. Arai S, Takeuchi S, Fukuda K, Taniguchi H, Nishiyama A, Tanimoto A, Satouchi M, Yamashita K, Ohtsubo K, Nanjo S, Kumagai T, Katayama R, Nishio M, Zheng MM, Wu YL, Nishihara H, Yamamoto T, Nakada M, Yano S. Osimertinib overcomes alectinib resistance caused by amphiregulin in a leptomeningeal carcinomatosis model of ALK-rearranged lung cancer. **J Thorac Oncol** 2020;15:752-65.
12. Takeuchi S, Hase T, Shimizu S, Ando M, Hata A, Murakami H, Kawakami T, Nagase K, Yoshimura K, Fujiwara T, Tanimoto A, Nishiyama A, Arai S, Fukuda K, Katakami N, Takahashi T, Hasegawa Y, Ko TK, Ong ST, Yano S. Phase I study of vorinostat with gefitinib in BIM deletion polymorphism/EGFR mutation double-positive lung cancer. **Cancer Sci** 2020;111:561-70.
13. Suzuki C, Kiyota N, Imamura Y, Rikitake J, Sai S, Koyama T, Hyogo Y, Nagatani Y, Funakoshi Y, Toyoda M, Otsuki N, Nibu KI, Minami H. Effect of tumor burden and growth rate on treatment outcomes of nivolumab in head and neck cancer. **Int J Clin Oncol** 2020 Jul;25(7):1270-7. doi: 10.1007/s10147-020-01669-y.

(共同研究)

1. Kanno A, Yasuda I, Irisawa A, Hara K, Ashida R, Iwashita T, Takenaka M, Katanuma A, Takikawa T, Kubota K, Kato H, Nakai Y, Ryozawa S, Kitano M, Isayama H, Kamata H, Okabe Y, Hanada K, Ohtsubo K, Doi S, Hisai H, Shibukawa G, Imazu H, Masamune A. Adverse events of Endoscopic Ultrasound-Guided Fine-Needle Aspiration for Histologic Diagnosis in Japanese Tertiary Centers: A Multicenter Retrospective Study. **Dig Endosc** 2020 Dec 7. doi: 10.1111/den.13912. Online ahead of print.
2. Saifullah, Sakari M, Suzuki T, Yano S, Tsukahara T. Effective RNA knockdown using CRISPR-Cas13a and molecular targeting of the EML4-ALK transcript in H3122 lung cancer cells. **Int J Mol Sci** 2020 Nov 24;21(23):E8904.
3. Sakai K, Nishiuchi T, Tange S, Suzuki Y, Yano S, Terashima M, Suzuki T, Matsumoto K. Proteasomal degradation of polycomb-group protein CBX6 confers MMP-2 expression essential for mesothelioma invasion. **Sci Rep** 2020 Oct 7;10(1):16678.
4. Hirata E, Ishibashi K, Kohsaka S, Shinjo K, Kojima S, Kondo Y, Mano H, Yano S, Kiyokawa E, Sahai E. The brain microenvironment induces DNMT1 suppression and indolence of metastatic cancer cells. **iScience** 2020 Aug 20;23(9):101480.
5. Lim K, Kodera N, Wang H, Mohamed M, Hazawa M, Kobayashi A, Yoshida T, Hanayama R, Yano S, Ando T, Wong R. High-speed AFM reveals molecular dynamic of human influenza A hemagglutinin and its interaction with exosomes. **Nano Letters** Sep 9;20(9):6320-8.
6. Shimokawa M, Nosaki K, Seto T, Ohashi K, Morise M, Horinouchi H, Sakakibara J, Murakami H, Yano S, Satouchi M, Matsumoto S, Goto K, Yoh K. Phase II, open-label, multicenter trial of crizotinib in Japanese patients with advanced non-small cell lung cancer

harboring a MET gene alteration: Co-MET study. **Trials** 2020 Mar 30;21(1):298.

7. Okura N, Nishioka N, Yamada T, Taniguchi H, Tanimura K, Katayama Y, Yoshimura A, Watanabe S, Kikuchi T, Shiotsu S, Kitazaki T, Nishiyama A, Iwasaku M, Kaneko Y, Uchino J, Uehara H, Horinaka M, Sakai T, Tanaka K, Kozaki R, Yano S, Takayama K. ONO-7475, a novel AXL inhibitor, suppresses the adaptive resistance to initial EGFR-TKI treatment in *EGFR*-mutated non-small lung cancer. **Clin Cancer Res** 2020;26:2244-56.
8. Nakamura Y, Taniguchi H, Ikeda M, Bando H, Kato K, Morizane C, Esaki T, Komatsu Y, Kawamoto Y, Takahashi N, Ueno M, Kagawa Y, Nishina T, Kato T, Yamamoto Y, Furuse J, Denda T, Kawakami H, Oki E, Nakajima T, Nishida N, Yamaguchi K, Yasui H, Goto M, Matsuhashi N, Ohtsubo K, Yamazaki K, Tsuji A, Okamoto W, Tsuchihara K, Yamanaka T, Miki I, Sakamoto Y, Ichiki H, Hata M, Yamashita R, Ohtsu A, Odegaard JI, Yoshino T. Clinical utility of circulating tumor DNA sequencing in advanced gastrointestinal cancer: SCRUM-Japan GI-SCREEN and GOZILA studies. **Nat Med** 2020; <https://doi.org/10.1038/s41591-020-1063-5>.
9. Han X, Sato M. DWnt4 and DWnt10 globally regulate the morphogenesis and arrangement of the columnar structures through Fz2/PCP signaling in the fly medulla. **Cell Reports** 2020, 33(4):108305.
10. Liu C, Trush O, Han X, Wang M, Takayama R, Yasugi T, Hayashi T, Sato M. Dscam1 establishes the columnar units through lineage-dependent repulsion between sister neurons in the fly brain. **Nature Commun** 2020, 11(1):4067.

著書・総説

1. 矢野聖二. 第 5 章 耐性メカニズムとその克服方法. チロシンキナーゼ阻害薬 (TKI) 耐性の分子機構アップデート 実験医学 38(15):150-6, 2020
2. 矢野聖二. 肺がんの中脳神経系転移と分子標的薬耐性. 分子呼吸器病 24(3):6-8, 2020
3. 大坪公士郎, 矢野聖二. I 総論 4 がん診断 2 がんにかかる主要症候 (がんの症候学) 入門腫瘍内科学 日本臨床腫瘍学会 編集 南江堂 53-5, 2020
4. 大坪公士郎. 中沼安二, 古川 徹, 福村由紀. IV 章 診断アプローチ 2 超音波内視鏡下穿刺吸引法 (EUS-FNA). 膵臓を診る医師のための膵臓病理テキスト 南江堂 239-43, 2020
5. 西山明宏. 中脳神経病変での TRK 阻害薬耐性. Medical Science Digest 7 月臨時増刊号 526-9, 2020
6. 谷本 梢, 矢野聖二. ROS1/RET/BRAF 遺伝子変異肺癌の治療. 呼吸器ジャーナル 特集 進行期肺癌治癒への道～がんゲノム医療と免疫プレシジョン医療の接

点～ 68(3): 390-400, 2020

<学会発表>

1. 第 117 回日本内科学会講演会 谷本 梓, 松本慎吾, 後藤功一, 矢野聖二. ALK 融合遺伝子陽性肺癌における p53 の機能低下に起因する ALK 阻害薬耐性の克服治療の開発. 2020 年 8 月 東京
2. 医学生・研修医の日本内科学会ことはじめ 2020 佐藤成樹, 谷本 梓, 吉田好雄, 林 龍二, 小泉知展, 中沢洋三, 伊藤研一, 浦本秀隆, 西野善一, 矢野聖二. 北信地域における障がい者のがん医療の実態を明らかにするための後方視的検討. 2020 年 8 月 東京
3. 第 29 回日本がん転移学会学術集会・総会 新井祥子, 竹内伸司, 福田康二, 西山明宏, 谷本 梓, 谷口寛和, 片山量平, 山本卓志, 矢野聖二. EML4-ALK 肺癌の髄膜癌腫症モデルにおける amphiregulin に起因するアレクチニブ耐性の克服. 2020 年 7 月 紙上発表
4. 第 24 回日本がん分子標的治療学会学術集会 柳村尚寛, 竹内伸司, 福田康二, 新井祥子, 谷本 梓, 西山明宏, 矢野聖二. ALK 融合遺伝子陽性肺癌における STAT3 阻害薬の併用によるアポトーシス抵抗性の克服. 2020 年 10 月 徳島
5. 第 79 回日本癌学会学術総会 (臓器別シンポジウム) Yano S. Circumvention of targeted drug tolerance of lung cancer. 2020 年 10 月 広島.
6. 第 36 回日本癌学会市民公開講座 矢野聖二. 研究が切り拓く がん治療の最前线. 2020 年 10 月 広島.
7. 第 79 回日本癌学会学術総会 Nishiyama A, Arai S, Fukuda K, Sato S, Yanagimura N, Takeuchi S, Suzuki C, Tanimoto A, Yamashita K, Takeuchi S, Ohtsubo K, Yano S. Mechanisms of targeted drug resistance in central nervous system (CNS) 2020 年 10 月 広島
8. 第 79 回日本癌学会学術総会 Fukuda K, Otani S, Takeuchi S, Nanjo S, Tanimoto A, Nishiyama A, Yano S. MEK inhibitor overcomes resistance to osimertinib caused by KRAS mutation in a LMC model of EGFR-mutant lung cancer. 2020 年 10 月 広島
9. 第 61 回日本肺癌学会学術集会 竹内伸司. 開発中の分子標的薬のバイオマーカ

一. 2020 年 11 月 岡山

<学会発表・国際>

1. Sixth AACR-IASCL International Joint Conference: Lung Cancer Translational Science from the Bench to the Clinic. Yano S. Mechanism of alectinib resistance in a leptomeningeal carcinomatosis of EML4-ALK lung cancer and its circumvention by EGFR-TKIs. 2020 年 1 月 San Diego, CA, USA.